Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Leukosite (LKST)promising new biotech Cy? -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Happy who wrote (2)	1/25/1998 12:32:00 AM
From: Larry Liebman	Read Replies (3) \| Respond to of 35

LKST, with its biotech brethren, has managed to decline in spite of what appears to be quite favorable prospects-and positive news within the last month, e.g., a collaboration with Genentech and an on-going expansion of its Warner-Lambert partnership. Business Week(1/26) featured an article on the next generation of AIDS "weapons" and mentioned LKST several times. There are a number of biotechs with relatively low valuations with particularly promising products in or near the clinic. In addition to LKST, it appears that ONXX, ENMD, and ALXN, are interesting speculations.